Comparison WAC of Herceptin vs biosimilars in the U.S. Q2 2020
As of Q2 2020, the wholesale acquisition cost of cancer drug Herceptin was around 4,364 U.S. dollars, compared to 3,927 U.S. dollars for the biosimilar Herzuma. Thus, biosimlars were able to rduce the cost between 10 and 22 percent. This statistic illustrates a comparison of the WAC of Herceptin vs biosimilars in the United States, as of Q2 2020.
